Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going

In this online program, experts discuss best practices and emerging strategies in CAR T-cell therapy for patients with leukemia, lymphoma, and myeloma. Watch the on-demand Webcast, download the slides from a dynamic CCO symposium in Orlando, and read expert commentaries to learn more about how to integrate CAR T-cells into your clinical practice.
Matthew J. Frigault, MD
Jae H. Park, MD
person default
Stephen J. Schuster, MD

ClinicalThought

Review my approach to CAR T-cell therapy—including considerations for patient candidacy and managing toxicities—illustrated with a patient case from my practice.

person default Stephen J. Schuster, MD Released: October 17, 2019

In this commentary, Matthew J. Frigault, MD, highlights key studies of CAR T-cell therapy that will be presented at the upcoming 2019 ASH annual meeting in Orlando.

Matthew J. Frigault, MD Released: December 4, 2019

Read expert answers to audience questions from a recent symposium on current best practices and emerging directions in CAR T-cell therapy.

Jae H. Park, MD Released: March 24, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Celgene Corporation
Kite, A Gilead Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue